PCSK9 inhibitor evolocumab reduces adverse cardiovascular events
PCSK9 Inhibitor Evolocumab Significantly Reduces Adverse Cardiovascular Events When Added to Statin Therapy With No Major Safety Concerns Data from the first successfully completed dedicated...







